Literature DB >> 16445302

Incorporating carer effects into economic evaluation.

Simon Dixon1, Mel Walker, Sam Salek.   

Abstract

BACKGROUND: Despite great interest in the development of methods used in the economic evaluation of health technologies, the effects of carer costs and quality of life (QOL) on the cost effectiveness of treatments has not been widely explored. Yet carer effects are clearly evident in the literature and relevant to the perspective of many published economic evaluations.
OBJECTIVE: To examine whether patient QOL is associated with carer time and carer QOL.
METHODS: We used two datasets to investigate carer effects. Firstly, we used 40,312 cases from the Health Outcomes Data Repository (HODaR) to assess the relationship between patient utility, using the EuroQoL (EQ)-5D, and the number of days care needed from friends and relatives. The stability of the relationship across patient subgroups was assessed by replicating the analysis in ten disease groups. Secondly, we used 64 cases from a study of patients with Alzheimer's disease and their primary carer. These data allowed us to estimate the relationships between patient and carer utility, using the EQ-5D, and patient utility and carer burden using the Community Dementia Quality of Life Profile (CDQLP).
RESULTS: For carer time, a linear model showed that each 0.1-point reduction in patient utility was associated with a 2.5-day increase in carer time over a 6-week period. A more general model, based on EQ-5D domain scores, was better specified and showed that decreased functioning within each domain is associated with increased carer time. Problems with self-care and usual activities have the greatest impact on carer time. These models do not appear to be stable across different disease groups. For carer utility, the relationships between carer and patient utility have low explanatory power and are poorly specified. A clearer relationship is shown between carer burden and utility, such that when sociodemographic covariates are introduced, the relationship reaches conventional levels of statistical significance (p < 0.05).
CONCLUSIONS: The preliminary work described here shows that improving patient QOL may reduce the need for carer time and improve carer QOL. Incorporating such effects into economic evaluations will change cost-per-QALY estimates, with the size of reduction dependent on the domains of health affected by treatment. Clinical studies need to capture carer data so that we can better understand these effects, and how they impact on economic evaluation.

Entities:  

Mesh:

Year:  2006        PMID: 16445302     DOI: 10.2165/00019053-200624010-00004

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  26 in total

Review 1.  Economic valuation of informal care. An overview of methods and applications.

Authors:  Bernard van den Berg; Werner B F Brouwer; Marc A Koopmanschap
Journal:  Eur J Health Econ       Date:  2004-02

2.  Informal costs of dementia care: estimates from the National Longitudinal Caregiver Study.

Authors:  M J Moore; C W Zhu; E C Clipp
Journal:  J Gerontol B Psychol Sci Soc Sci       Date:  2001-07       Impact factor: 4.077

3.  The effect of rheumatoid arthritis on the quality of life of primary caregivers.

Authors:  M M das Chagas Medeiros; M B Ferraz; M R Quaresma
Journal:  J Rheumatol       Date:  2000-01       Impact factor: 4.666

4.  The routine collation of health outcomes data from hospital treated subjects in the Health Outcomes Data Repository (HODaR): descriptive analysis from the first 20,000 subjects.

Authors:  Craig J Currie; Phil McEwan; John R Peters; Tunia C Patel; Simon Dixon
Journal:  Value Health       Date:  2005 Sep-Oct       Impact factor: 5.725

5.  Caregiving as a risk factor for mortality: the Caregiver Health Effects Study.

Authors:  R Schulz; S R Beach
Journal:  JAMA       Date:  1999-12-15       Impact factor: 56.272

6.  Economic and psychologic costs for maternal caregivers of gastrostomy-dependent children.

Authors:  Melvin B Heyman; Paul Harmatz; Michael Acree; Leslie Wilson; Judith Tedlie Moskowitz; Steve Ferrando; Susan Folkman
Journal:  J Pediatr       Date:  2004-10       Impact factor: 4.406

7.  The Caregiver Quality of Life Cystic Fibrosis (CQOLCF) scale: modification and validation of an instrument to measure quality of life in cystic fibrosis family caregivers.

Authors:  Whitney Boling; David M Macrina; John P Clancy
Journal:  Qual Life Res       Date:  2003-12       Impact factor: 4.147

8.  Impact of rivastigmine on costs and on time spent in caregiving for families of patients with Alzheimer's disease.

Authors:  Deborah Marin; Karine Amaya; Roman Casciano; Katherine L Puder; Julian Casciano; Sobin Chang; Edward H Snyder; Isaac Cheng; Anthony J Cuccia
Journal:  Int Psychogeriatr       Date:  2003-12       Impact factor: 3.878

9.  [Health-related quality of life assessed by EuroQol in caregivers of home care stroke patients].

Authors:  Akiko Kuroda; Tadashi Kanda; Noriyoshi Asai
Journal:  Nihon Ronen Igakkai Zasshi       Date:  2003-07

10.  Quality of life in spinal cord injured individuals and their caregivers during the initial 6 months following rehabilitation.

Authors:  Kathleen T Lucke; Holly Coccia; Joseph S Goode; Joseph F Lucke
Journal:  Qual Life Res       Date:  2004-02       Impact factor: 4.147

View more
  21 in total

1.  Estimating informal care inputs associated with EQ-5D for use in economic evaluation.

Authors:  Donna Rowen; Simon Dixon; Mónica Hernández-Alava; Clara Mukuria
Journal:  Eur J Health Econ       Date:  2015-08-15

2.  Too important to ignore: informal caregivers and other significant others.

Authors:  Werner B F Brouwer
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 3.  Does including informal care in economic evaluations matter? A systematic review of inclusion and impact of informal care in cost-effectiveness studies.

Authors:  Marieke Krol; Jocé Papenburg; Job van Exel
Journal:  Pharmacoeconomics       Date:  2015-02       Impact factor: 4.981

4.  Expanding the Scope of Costs and Benefits for Economic Evaluations in Health: Some Words of Caution.

Authors:  Christopher McCabe
Journal:  Pharmacoeconomics       Date:  2019-04       Impact factor: 4.981

5.  The influence of chronic heart failure in patient-partner dyads--a comparative study addressing issues of health-related quality of life.

Authors:  Susanna Ågren; Lorraine Evangelista; Thomas Davidson; Anna Strömberg
Journal:  J Cardiovasc Nurs       Date:  2011 Jan-Feb       Impact factor: 2.083

Review 6.  A review of the health-related quality of life and economic impact of Parkinson's disease.

Authors:  Clare H Dowding; Claire L Shenton; Sam S Salek
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 7.  Health state values for use in the economic evaluation of treatments for Alzheimer's disease.

Authors:  James Shearer; Colin Green; Craig W Ritchie; John P Zajicek
Journal:  Drugs Aging       Date:  2012-01-01       Impact factor: 3.923

8.  Evidence of spillover of illness among household members: EQ-5D scores from a US sample.

Authors:  Eve Wittenberg; Grant A Ritter; Lisa A Prosser
Journal:  Med Decis Making       Date:  2012-10-25       Impact factor: 2.583

9.  Variation in the spillover effects of illness on parents, spouses, and children of the chronically ill.

Authors:  Tara A Lavelle; Eve Wittenberg; Kara Lamarand; Lisa A Prosser
Journal:  Appl Health Econ Health Policy       Date:  2014-04       Impact factor: 2.561

10.  Quality of life as an outcome in Alzheimer's disease and other dementias--obstacles and goals.

Authors:  Matthias W Riepe; Thomas Mittendorf; Hans Förstl; Lutz Frölich; Martin Haupt; Reiner Leidl; Christoph Vauth; Matthias Graf von der Schulenburg
Journal:  BMC Neurol       Date:  2009-08-25       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.